Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.

Abstract: A transparent tubing is provided comprising a longitudinal axis having a center; an inner circumferential surface defining a fluid pathway therethrough for delivering a first medium having a first index of refraction m; an outer circumferential surface; at least one visual marker; and, at least one integrated lens disposed opposite from the at least one visual marker, the at least one integrated lens configured to direct light from the at least one visual marker for detecting a presence or an absence in the fluid pathway of a second medium having a second index of refraction n2, where n2 is different from the first index of refraction n1. A method of making transparent tubing having at least one integrated lens is also provided.

Abstract: A computing device is provided having a processor in communication with a memory configured to store machine-readable instructions. The processor can receive, from a wireless communication interface of a medication delivery device, an advertising packet comprising injection event information generated by the medication delivery device, analyze contextual data associated with the advertising packet to determine validation data, and choose, based on the validation data, between implementing any two or three of the following actions: (i) include the injection event information in a medication log, (ii) prompt a user for additional information, or (iii) ignore the advertising packet. The medication delivery device comprises (a) a reservoir configured to hold medication, (b) an actuating button for initiating an injection of the medication, and (c) a processing circuit in communication with the wireless communication interface.

Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

Abstract: The present disclosure relates to a dose detection system for use in combination with a medication delivery device in which a dose setting member rotates relative to an actuator during dose delivery. The dose detection system includes a module which is removably attached to the medication delivery device. The module includes a dosing component attached to the actuator during dose delivery. The dosing component includes a light source and a light sensor. A sensed element is attached to the dose setting member and includes surface features detectable by the light sensor.

Abstract: The present invention provides a compound of Formula I: wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and lupus nephritis.

Abstract: Methods and systems are provided for evaluating injection sites on a body of a patient. The methods/systems may instruct a patient to place one or more capacitance sensors in contact with a potential injection site on the body of the patient. The methods/systems may also comprise using a processing circuit to receive data indicative of a capacitance of body tissue at the potential injection site, as measured by the one or more capacitance sensors. The methods/systems may also comprise generating, using the processing circuit, an indication of a level of pain that would be expected to be experienced by the patient from a potential injection at the potential injection site based on the received capacitance.

Abstract: The present disclosure relates to a method of administering a medication with a dose detection system in combination with a medication delivery device. In one aspect, the system includes a module body adapted to be removably attached to the actuator of a medication delivery device, and a plurality of magnetic sensing elements attached to said module body. The magnetic sensing elements can be spaced apart from one another to define a ring pattern. The system detects the amount of rotation of a magnetic ring of said one or more dipoles of a medication delivery device relative to the magnetic sensing elements during dose delivery when the module is attached to the device.

Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.

Abstract: The present invention provides a compound of formula or a pharmaceutical salt thereof, use, methods for its preparation are described.

Abstract: The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.

Abstract: A therapeutic agent delivery system (10) includes a housing (16) and a drive wheel (38) rotatably carried by the housing. A plunger rod (50) may be rotatable with the drive wheel relative to the housing from a first rotational configuration to a second rotational configuration. The plunger rod may be translatable relative to the housing from a first translational configuration to a second translational configuration. A plunger restraint (58) may maintain the plunger rod in the first translational configuration when the plunger rod is disposed in the first rotational configuration. The plunger restraint may permit the plunger rod to translate to the second translational configuration when the plunger rod is disposed in the second rotational configuration. A needle may move from a stowed configuration to a deployed configuration by the plunger rod when the plunger rod moves from the first translational configuration to the second translational configuration.

Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.

Abstract: This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof, and methods of using the same to treat pain associated with AT2R activity.

Abstract: The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

Abstract: A novel salt of treprostinil and methods of its preparation and use are disclosed.

Abstract: A medical delivery device for advancing a piston in a medicament container to expel a medicament. A support structure supports the container and a drive assembly that advances the piston. The drive assembly includes a drive ribbon that can be retracted and extended. The retracted ribbon defines a spiral and the extended ribbon defines a helix. The drive ribbon is incrementally moveable between the retracted spiral configuration and extended helical configuration. A mechanical drive rotates the drive ribbon to selectively extend and retract the ribbon. A thrust member having a helical ramp engages a proximal edge of the drive ribbon where it transitions between a spiral and helix. A bearing member at the distal end of the drive ribbon exerts an axial force on the piston when the ribbon is extended.

Abstract: The embodiments of present invention provide processes for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes. Additionally, embodiments of the present invention provide tablets including 25 mg, 50 mg, 100 mg, or 200 mg free base equivalent of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate.